Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En forskningsstudie i barn født små og som forble små. Behandlingen er Somapacitan én gang i uken sammenlignet med Norditropin® én gang om dagen

5. oktober 2026 oppdatert av: Novo Nordisk A/S

En dosesøkende studie som evaluerer effekten og sikkerheten av behandling en gang i uken av Somapacitan sammenlignet med daglig Norditropin® hos barn med kort vekst født små for svangerskapsalder uten vekst etter 2 års alder eller eldre

The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).

Participants will either get somapacitan or Norditropin® - which treatment is decided by chance. Both participants and the study doctor will know which treatment the participants get. The study will last for 5 years. Participants will take either an injection once every week or once every day.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

62

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Algiers, Algerie, 16000
        • CHU Bab El Oued Pediatrics Dept
      • Algiers, Algerie, 16000
        • Endo and Diab Dept El Oued
      • Constantine, Algerie, 25000
        • endocrino-diabetology department, Hospital IBN BADIS.
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2B7
        • Stollery Children's Hospital
      • Copenhagen Ø, Danmark, 2100
        • Rigshospitalet Klinik for Vækst og Reproduktion Afsnit 5064
      • Tallinn, Estland, 13419
        • Tallinn Children's Hospital
      • Tartu, Estland, 50406
        • Tartu University Hospital Children's Clinic
    • Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • Univ of AL at Birmingham_BRM
    • California
      • Orange, California, Forente stater, 92868
        • Children's Hosp Of Orange
    • Idaho
      • Boise, Idaho, Forente stater, 83712
        • St. Luke's Children's Endo
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55454
        • Univ of Minnesota M.C.H.
      • Saint Paul, Minnesota, Forente stater, 55102
        • Children's Minnesota
    • New Jersey
      • Morristown, New Jersey, Forente stater, 07962
        • Goryeb Children's Hospital
      • New Brunswick, New Jersey, Forente stater, 08901
        • Rutgers-Rwjms
    • New York
      • Garden City, New York, Forente stater, 11530
        • NYU Langone Hospital-LI
      • Mineola, New York, Forente stater, 11501
        • NYU Langone Hospital-LI
      • New York, New York, Forente stater, 10029
        • Icahn Sch of Med-Mt Sinai Hosp
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45229
        • CCHMC_Cinc
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • Univ Oklahoma Sci Ctr OK City
    • Texas
      • Fort Worth, Texas, Forente stater, 76104
        • Cook Children's Hospital-Hematology-Oncology
    • Washington
      • Tacoma, Washington, Forente stater, 98405
        • MultiCare Inst for Res & Innov
      • Angers, Frankrike, 49100
        • Centre Hospitalier Universitaire D'Angers-2
      • Le Kremlin-Bicêtre, Frankrike, 94270
        • AP-HP-HOPITAL DE BICETRE_Service d'Endocrinologie pédiatrique
      • Marseille, Frankrike, 13005
        • Assistance Publique Hopitaux de Marseille-Hopital de La Timone-2
      • Marseille Cédex 05, Frankrike, 13385
        • Hopital de La Timone
      • Paris, Frankrike, 75015
        • Ap-Hp-Hopital Necker
      • Paris, Frankrike, 75015
        • Hôpital Necker
      • Toulouse, Frankrike, 31059
        • HOPITAL DES ENFANTS-HOPITAL PAULE DE VIGUIER - Pharmacie
    • Kerala
      • Kochi, Kerala, India, 682041
        • Amrita Institute Of Medical Sciences & Research Centre
    • Maharashtra
      • Pune, Maharashtra, India, 411001
        • Jehangir Clinical Development Centre
    • New Delhi
      • New Dehli, New Delhi, India, 110029
        • All India Institute of Medical Sciences
      • Dublin, Irland, D12 N512
        • CHI Crumlin Dept of Endocrinology
      • Haifa, Israel, 31096
        • Rambam MC - Department of Pediatrics A
      • Kfar Saba, Israel, 44281
        • Meir MC - Department of Paediatrics
      • Petah Tikva, Israel, 49202
        • Schneider MC - Endrocrinology and Diabetes
      • Florence, Italia, 50139
        • IRCCS Meyer Firenze
      • Genova, Italia, 16147
        • Ospedale Pediatrico Gaslini
      • Milan, Italia, 20122
        • Ospedale Maggiore Policlinico UO Endocrinologia Diabetolgia
      • Roma, Italia, 00165
        • Ospedale Pediatrico Bambino Gesu
      • Fukuoka, Japan, 830-0011
        • Kurume University Hospital, Pediatrics
      • Fukuoka-shi, Fukuoka, Japan, 813-0017
        • Fukuoka Children's Hospital_Endocrinology and Metabolism
      • Fukuoka-shi, Fukuoka, Japan, 813-0017
        • Fukuoka Children's Hospital
      • Fukuyama-shi, Hiroshima, Japan, 721-8511
        • Fukuyama City Hospital_Department of Pediatrics
      • Kobe-shi, Hyogo, Japan, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital Dept. Metab & endo
      • Kobe-shi, Hyogo, Japan, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital_Metab & endo
      • Kyoto, Japan, 602-8566
        • Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics
      • Nara-shi, Nara, Japan, 630-8581
        • Nara Prefecture General Medical Center_ Nara-shi, Nara
      • Nara-shi, Nara, Japan, 630-8581
        • Nara Prefecture General Medical Center_Pediatric
      • Niigata-shi, Niigata, Japan, 951 8520
        • Niigata University Medical & Dental Hospital_Pediatrics
      • Osaka, Japan, 534-0021
        • Osaka City General Hospital, Pediatric Endocrinology and Me
      • Osaka, Japan, 594-1101
        • Osaka Women's and Children's Hospital
      • Saitama-shi, Saitama, Japan, 330-8777
        • Saitama Children's Medical Center, Endocrinorogy&Metabolism
      • Tokyo, Japan, 157 8535
        • National Center for Child Health and Dev, Endo and Metabo
      • Tokyo, Japan, 113-8519
        • Institute of Science Tokyo Hospital
      • Tokyo, Japan, 113-8519
        • Institute of Science Tokyo Hospital_Pediatrics
      • Tokyo, Japan, 157 8535
        • National Center for Child Health and Development_Endo and Metabo
      • Tokyo, Japan, 160-8582
        • Keio University Hospital_Pediatrics
      • Riga, Latvia, 1004
        • Children's Clinical University Hospital
      • Bergen, Norge, 5021
        • Haukeland Universitetssykehus, Barneklinikken
      • Szczecin, Polen, 71-252
        • SPSK nr 1 im Prof. T Sokolowskiego
      • Warsaw, Polen, 04-730
        • Instytut ''Pomnik - Centrum Zdrowia Dziecka''
      • Izhevsk, Russland, 426009
        • Republic Children's Hospital of Ministry of Health of Udmurt
      • Moscow, Russland, 119435
        • Setchenov First Moscow State Medical University
      • Moscow, Russland, 125373
        • RMAPE
      • Novosibirsk, Russland, 630048
        • Children's clinical city hospital #1
      • Rostov-on-Don, Russland, 344013
        • FSBEI of Higher Education "Rostov State Medical University"
      • Saint Petersburg, Russland, 191144
        • SPSBHI City Children out-patient clinic #44
      • Samara, Russland, 443079
        • Samara Regional Children Clinical Hospital n.a. N.N. Ivanova
      • Tomsk, Russland, 634050
        • Siberian State Medical University
      • Belgrade, Serbia, 11000
        • University Children's Hospital Tirsova
      • Belgrade, Serbia, 11070
        • Institute for Mother and Child Health Care of Serbia
      • Kragujevac, Serbia, 34000
        • University Clinical Centre Kragujevac
      • Niš, Serbia, 18 000
        • Clinical Center in Nis
      • Novi Sad, Serbia, 21000
        • Institute for Health Care of Children and Adolescents
      • Esplugues Llobregat(Barcelona), Spania, 08950
        • Hospital Sant Joan de Déu
      • Santiago de Compostela, Spania, 15706
        • Hospital Clínico de Santiago de Compostela
      • Hull, Storbritannia, HU3 2JZ
        • Hull Royal Infirmary
      • Liverpool, Storbritannia, L12 2AP
        • Alder Hey Children's Hospital
      • London, Storbritannia, E1 1BB
        • Royal London Hospital_London
      • Manchester, Storbritannia, M13 9WL
        • Royal Manchester Children's Hospital
      • Bern, Sveits, 3010
        • Med. Kinder- und Poliklinik
      • Zurich, Sveits, 8032
        • Kinderspital Endokrinologie, Zürich
      • Bangkok, Thailand, 10330
        • King Chulalongkorn Memorial hospital-Ped-Endocrinology
      • Bangkok, Thailand, 10330
        • King Chulalongkorn Memorial hospital_Ped-Endocrinology
      • Bangkok, Thailand, 10400
        • Phramongkutklao Hospital_Ped-Endo_Pediatrics
      • Dnipro, Ukraina, 49100
        • Dnipropetrovsk Regional Children's Clinical Hospital - Endocrinology department
      • Kharkiv, Ukraina, 61093
        • Kharkiv Regional Children's Clinical Hospital - Endocrinological department
      • Kyiv, Ukraina, 04114
        • Komisarenko Institute of Endocrinology and Metabolism of NAMSU - Department of paediatric endocrine pathology
      • Budapest, Ungarn, 1023
        • Észak-Közép-budai Centrum, Szent János Kórház és Szakrendelő
      • Szeged, Ungarn, 6720
        • Szegedi Tudományegyetem Gyermekgyógyászati Klinika
      • Graz, Østerrike, 8036
        • Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie
      • Salzburg, Østerrike, A 5020
        • LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde
      • Sankt Pölten, Østerrike, 3100
        • LKH St. Poelten, Kinder-und Jugendheilkunde
      • Vöcklabruck, Østerrike, 4840
        • Salzkammergut-Klinikum Vöcklabruck
    • Upper Austria
      • Linz, Upper Austria, Østerrike, 4020
        • Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 år til 11 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Pre-pubertal children, boys:

    1. age between 2.5 and 11.0 years at screening.
    2. testes volume below 4 ml.
  • Pre-pubertal children, girls:

    1. age between 2.5 and 10.0 years at screening.
    2. Tanner stage 1 for breast development (no palpable glandular breast tissue).
  • Born small for gestational age (birth length and/or weight below -2 standard deviation scores) (according to national standards).

  • Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and gender at screening according to the standards of Centers for Disease Control and Prevention at screening.

  • Impaired height velocity defined as annualized height velocity below the 50th percentile for chronological age and gender according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening.

  • No prior exposure to growth hormone therapy or Insulin-like Growth Factor-I (IGF-I) treatment.

Exclusion Criteria:

  • Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements.
  • Children with hormonal deficiencies including suspected or confirmed growth hormone deficiency according to local practise.
  • Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening.
  • Children requiring inhaled glucocorticoid therapy at a dose of greater than 400 μg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening.
  • Concomitant administration of other treatments that may have an effect on growth, e.g but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder.
  • Diagnosis of attention deficit hyperactivity disorder.
  • Prior history or presence of malignancy including intracranial tumours.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Somapacitan 0.24 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Eksperimentell: Somapacitan 0.20 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Eksperimentell: Somapacitan 0.16 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Aktiv komparator: Norditropin® 0.035 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

Aktiv komparator: Norditropin® 0.067 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Height Velocity
Tidsramme: Baseline (week 0); week 26

Height velocity (HV) was derived from height measurements taken at baseline (week 0) and week 26 visit as: HV = (height at 26 weeks visit - height at baseline)/(time from baseline to 26 weeks visit in years). The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Ratio of Bone Age Versus Chronological Age
Tidsramme: Baseline (week 0); week 52

Change in ratio of bone age (years) versus chronological age (years) from baseline (week 0) to week 52 is presented. X-rays of left hand and wrist for bone age assessment according to the Greulich and Pyle atlas were taken. X-ray images were sent to a central imaging laboratory for evaluation. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 52 or last trial contact, whichever came first.

Baseline (week 0); week 52
Change in Height Standard Deviation Score (HSDS)
Tidsramme: Baseline (week 0); week 26

Change in HSDS from baseline (week 0) to week 26 is presented. HSDS was derived using Centre for Disease Control and Prevention (CDC) standards. HSDS = [(height/population median)^skewness - 1]/(skewness * population standard deviation) where skewness, median and standard deviation is given by a reference growth table for the corresponding chronological age. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. Positive value in change from baseline in HSDS indicated that HSDS was better than baseline HSDS In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Height Velocity Standard Deviation Score (HVSDS)
Tidsramme: Baseline (week 0); week 26

Change in HVSDS from baseline (week 0) to week 26 is presented. HVSDS was derived using Prader standards. HV SDS was calculated using the formula: HV SDS = (height velocity - mean)/standard deviation (SD), where height velocity was the height velocity variable measured, mean and SD of height velocity by gender and age for the reference population. The range for HVSDS was -10 to +10. Negative scores indicated a height velocity below the mean height velocity for a child with the same age and gender, whereas positive scores indicated a height velocity above the mean height velocity for a child with the same age and gender. Positive value in change from baseline in HVSDS indicated that HVSDS was better than baseline HVSDS. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Fasting Plasma Glucose
Tidsramme: Baseline (week 0); week 26

Change in fasting plasma glucose from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Steady State Beta Cell Function (HOMA-B)
Tidsramme: Baseline (week 0); week 26

Change in HOMA-B from baseline (week 0) to week 26 is presented. HOMA-B is a measure of the beta cell function and was calculated as follows: HOMA-B = (20 * fasting insulin (picomoles per liter [pmol/L]) * 1/6(microunit per milliliter [µU/mL]))/ FPG(mmol/L)-3.5). HOMA-beta score ranges from minus infinity to infinity (no limits). Higher score means better beta-cell function for HOMA-beta. Negative change from baseline (week 0) in HOMA-B indicated a worse outcome. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Tidsramme: Baseline (week 0); week 26

Change in HOMA-IR from baseline (week 0) to week 26 is presented. Insulin resistance is a condition in which cells fail to respond to normal actions of hormone in body. HOMA-IR is calculated using a participant's fasting plasma insulin and glucose levels. HOMA-IR = fasting serum insulin (micro international units per milliliter (μU/ml)) × fasting plasma glucose (millimoles per liter (mmol/l)) / 22.5. HOMA-IR scores are classified as follows: less than 1.0: considered insulin sensitive, 0.5-1.4: considered healthy, above 1.8: considered early insulin resistance; above 2.7 is considered significant insulin resistance. HOMA-IR score ranges from 0-infinity (no upper limit). Higher the score, higher the level of insulin resistance. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Glycated Haemoglobin (HbA1c)
Tidsramme: Baseline (week 0); week 26

Change in HbA1c from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor I (IGF-I) Standard Deviation Score (SDS)
Tidsramme: Baseline (week 0); week 26

Change in IGF-I SDS from baseline (week 0) to week 26 is presented. IGF-I SDS was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1. The range for IGF-I SDS was from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. Positive value in change from baseline in IGF-I SDS indicated that IGF-I SDS was higher than baseline IGF-I SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) SDS
Tidsramme: Baseline (week 0); week 26

Change in IGFBP-3 SDS from baseline (week 0) to week 26 is presented. The range for IGFBP-3 SDS was from -10 to +10. Negative scores indicated a IGFBP-3 below the mean IGFBP-3 for a child with the same age and gender, whereas positive scores indicated a IGFBP-3 above the mean IGFBP-3 for a child with the same age and gender. Positive value in change from baseline in IGFBP-3 SDS indicated that IGFBP-3 SDS was higher than baseline IGFBP-3 SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Clinical Reporting Anchor and Disclosure 1452, Novo Nordisk A/S

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. juli 2019

Primær fullføring (Faktiske)

5. mai 2021

Studiet fullført (Antatt)

23. desember 2026

Datoer for studieregistrering

Først innsendt

15. mars 2019

Først innsendt som oppfylte QC-kriteriene

15. mars 2019

Først lagt ut (Faktiske)

18. mars 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • NN8640-4245
  • 2018 (U.S. NIH-stipend/kontrakt)
  • U1111-1207-9741 (Annen identifikator: World Health Organization (WHO))
  • 2018-000232-10 (EudraCT-nummer)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere